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Abstract
Objective Hypothermia is an adverse drug reaction (ADR) of
antipsychoticdrug(APD)use.Riskfactorsforhypothermiain
ADP users are unknown. We studied which risk factors for
hypothermia can be identified based on case reports.
Method Case reports of hypothermia in APD-users found in
PUBMED or EMBASE were searched for risk factors. The
WHO international database for Adverse Drug Reactions was
searched for reports of hypothermia and APD use.
Results The literature search resulted in 32 articles contain-
ing 43 case reports. In the WHO database, 480 reports were
registered of patients developing hypothermia during the
use of APDs which almost equals the number of reports for
hyperthermia associated with APD use (n=524). Hypother-
mia risk seems to be increased in the first days following start
or dose increase of APs. APs with strong 5-HT2 antagonism
seem to be more involved in hypothermia; 55% of hypother-
mia reports are for atypical antipsychotics. Schizophrenia was
the most prevalent diagnosis in the case reports.
Conclusion Especially in admitted patients who are not able
to control their own environment or physical status, frequent
measurements of body temperature (with a thermometer that
can measure low body temperatures) must be performed in
order to detect developing hypothermia.
Keywords Antipsychoticagents.Hypothermia.
Thermoregulation.Adversedrugeffect.Schizophrenia
Introduction
Antipsychotic drugs (APDs) can influence thermoregula-
tion. Even before its psychotropic properties were clear in
the early 1950s, the first manufactured APD, chloroproma-
zine, was used to suppress compensatory responses to body
cooling in surgery (artificial hibernation) [1].
The hypothermic effects of APDs seem less well known
than the hyperthermic effects (e.g., malignant neuroleptic
syndrome). Besides occasional case reports, little emphasis
has been placed in scientific literature on hypothermia as
adverse drug reaction (ADR). To our knowledge, a review
of all reported and published cases of antipsychotic
associated hypothermia has not yet been published.
Methods
The WHO international database for Adverse Drug Reac-
tions was searched for reports of hypothermia and APD use
(ATC-code N05A, with exclusion of lithium). The data in
the database are collected from 77 countries participating in
the WHO Program for International Drug Monitoring. This
database comprises more than 3.5 million case reports, to
which around 50,000 new reports are added quarterly. The
relationship between the APD and hypothermia is evaluated
by calculating the Reporting Odds Ratios (RORs) and 95%
confidence intervals (95% CI) in a case/non-case design.
The ROR compares the frequency of the reported ADR for
a certain drug with the frequency of reports of that adverse
drug reaction for all other drugs in the database. Reports
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reports as non-cases. Index reports included all reports on
an APD (ATC code beginning with N05A, with exclusion
of lithium), all other reports were controls. When the
number of reports of hypothermia in association with the
APD is high and the number of reports of hypothermia in
association with other drugs is low, ROR will be high. This
also happens when the number of reports of other ADRs in
association with the APD is low and the number of reports
of other ADRs in association with other drugs is low. Since
the vast majority of cases in the WHO database do not
contain any details on indication of drug use, start and/or
end dates and outcome, these factors cannot be analyzed
with data from the WHO database. To get more information
regarding characteristics of patients developing hypother-
mia during APD use, we performed a literature search in
Medline and Embase for case reports with search terms
“(antipsychotic OR neuroleptic) AND (hypothermia OR
body temperature regulation), with no selection on date or
language. From these articles, we searched the references
Table 1 Antipsychotic drugs
and hypothermia: reports from
the WHO database
aROR= (a/c) / (b/d); (a = no. of
reports of adverse drug reaction
with suspected drug;
b = no. of reports of adverse
drug reaction in total database;
c = no. of reports regarding the
suspected drug in database;
d = total no. of reports in
database). ROR is only calcu-
lated for APDs with three or
more reports
Antipsychotic drug Number of reports
for hypothermia
Number of reports for
any ADR with this drug
Reported OR (CI)
a
for ADRs with ≥3 reports
Tioxanthenes
Zuclopenthixol 13 1094 15.88 (9.18–27.47)
Flupenthixol 6 1677 4.73 (2.12–10.55)
Chlorprothixen 4 502 10.58 (3.95–28.31)
Tiotixene 3 904 4.38 (1.41–13.62)
Clopenthixol 2 293 -
Phenothiazines
Thioridazine 23 4436 6.90 (4.57–10.41)
Chlorpromazine 16 6182 3.43 (2.09–5.60)
Levomepromazine 11 2348 6.21 (3.43–11.24)
Cyamemazine 9 1197 9.99 (5.18–19.27)
Periciazine 8 430 25,00 (12.41–50.36)
Pipothiazine 3 197 20.36 (6.50–63.71)
Fluphenazine 3 2656 1.49 (0.48–4.62)
Trifluoperazine 3 1895 2.09 (0.67–6.48)
Perphenazine 2 1522 -
Prochlorperazine 2 4451 -
Promazine 2 307 -
Mesoridazine 1 215 -
Butyrofenones
Haloperidol 32 10543 6.21 (3.43–11.24)
Pipamperone 10 546 24.62 (13.16–46.07)
Droperidol 2 1178 -
Benperidol 1 146 -
Benzamides
Tiapride 5 596 11.14 (4.62–26.89)
Sulpiride 4 1828 2.89 (1.08–7.70)
Amisulpiride 1 1514 -
Sultopride 1 72 -
Others
Loxapine 4 928 5.70 (2.13–15.23)
Pimozide 3 628 6.31 (2.03–19.65)
Zotepine 2 260 -
Prothipendyl 1 93 -
Penfluridol 1 58 -
Atypical
Risperidone 129 18431 9.65 (8.09–11.52)
Clozapine 68 44255 2.05 (1.61–2.61)
Olanzapine 44 16090 3.65 (2.71–4.91)
Quetiapine 21 5374 5.19 (3.38–7.98)
Aripiprazole 11 4566 3.18 (1.76–5.76)
Ziprasidone 8 2963 3.57 (1.78–7.15)
628 Eur J Clin Pharmacol (2007) 63:627–631for missing articles. Two reviewers judged all case reports.
All relevant case reports were studied for patient, drug and
environmental characteristics.
Results
In the WHO database, in January 2007, 480 reports were
registered of patients developing hypothermia during the
use of APDs. Characteristics of these reports are presented
in Table 1. In the same period, 524 reports of hyperthermia
associated with antipsychotic drug use were registered.
Based on the reports, no specific pharmacological subgroup
can be associated with an increased risk for hypothermia.
Atypical antipsychotics are responsible for 55% of the
reports, but this is mainly attributable to risperidone.
Risperidone alone was responsible for 27% of all reports.
A remarkable high association is found for pipamperone
(ROR:24.62; 95% CI 13.16–46.07), an antipsychotic drug
mainly used in Europe.
The literature search resulted in 32 articles containing 43
case reports (December 2006) [3–34] from which character-
istics are summarized in Table 2. Hypothermia following
antipsychotic drug use is not associated with a specific age
group. Reported ages vary from 0 to 90 years. In most
cases, hypothermia is detected shortly following the start or
dose increase of an antipsychotic drug. Most patients
suffered from schizophrenia.
Discussion
Hypothermia in patients using an APD is a serious,
unpredictable, type B adverse event frequently leading to
hospital and ICU admission and sometimes even to death.
Some authors have even suggested that a substantial
proportion of unexplained deaths should be attributed to
antipsychotic-induced hypothermia [3, 35]. No single
sufficient cause for hypothermia can be found in case
reports. First, drug-receptor profile may play a role.
Serotonin is associated with thermoregulation and APDs
with a stronger affinity for the 5-HT2a receptor than for the
D2-receptor (pipamperone, the atypical APDs) seem to be
associated with hypothermia. The high association for
relatively new drugs, like the atypical APDs, can partially
be explained by reporting bias (reporting incidence for
adverse drug effects is higher for new drugs and tends to
decline in time; the so-called Weber-effect), but the high
number of reports for risperidone should keep clinicians
alert. Blocking alpha2-adrenergic receptors (e.g., chloro-
promazine, risperidone, clozapine, thioridazine) may also
increase the hypothermic effect, by inhibiting peripheral
responses to cooling (vasoconstriction and shivering). Next
to this receptor profile, many patient-bound factors must be
considered. Patients with pre-existing brain damage may be
more susceptible to hypothermic effects. The pre-optic
anterior hypothalamic region regulates body temperature.
Animal studies show that lesions of this region give a
hypothermic response following administration of an APD
[36, 37]. In patients with multiple sclerosis, hypothermia is
also associated with thalamic lesions [38]. Studies in
schizophrenic patients show that core temperature decreases
following the administration of APDs [39, 40]. Our search
shows a predominance of case reports for schizophrenic
patients and little for other frequent APD user groups like
demented or delirious elderly. In schizophrenia, thermal
regulation is altered. This may be explained by changes in
neurotensine levels in schizophrenia. Neurotensine (NT) is
one of the most important thermoregulatory peptides that
also plays a role in the antipsychotic actions of APDs. In
schizophrenic patients, NT concentration in cerebro-spinal
fluid (CSF) is low and will be normalized following
antipsychotic drug use [41]. The hypothermic reaction is
also dependent on ambient temperature. In animal studies,
APD administration at ambient temperatures below 22°C
led to hypothermia, whereas APD administration in a room
temperature of 29°C gave no thermal response and at 32°C
an increase in rectal temperature [41, 42]. Normally, a cold
environment will result in behavior aimed at protection
against the cold (taking extra blankets or clothes). APDs,
however, will induce apathy and indifference, resulting in
unawareness of developing hypothermia. Since some case
reports also mention the co-existence of infections at the
Table 2 Characteristics of cases with hypothermia following antipsy-
chotic drug use in literature (43 case reports, 46 episodes)
Characteristics Data
Male 41%
Age: mean (SD) 49 (23.0)
Range 0–90 years
Reported body temperature: mean (SD) 32,6°C (2.7)
Range 20.0–36.1°C
Diagnosis known (n=35)
Schizophrenia 51%
Mental retardation 11%
Bipolar disorder 11%
Dementia 11%
Drug change Start or dose increase 80%
No change 16%
Interval drug change detection hypothermia
<2 days 57%
2–7 days 16%
Outcome death 4%
ICU admission 24%
Hospitalization (incl. prolonged) 69%
Eur J Clin Pharmacol (2007) 63:627–631 629time of development of hypothermia, this may also play a
role in the dysregulation of thermal homeostasis.
There is an ongoing discussion concerning the value of
case reports and spontaneous reports in the field of drug
safety. There can be no discussion that pharmacodiligence
requires prospective studies, access to regulatory filings for
controlled and monitored use of drugs, and some sense of
relative potency for comparison between different drug
entities. However, large cohorts are needed for the detection
and analysis of type B reactions. Since these data are
lacking, case and spontaneous reports by alert clinicians
must be analyzed [43]. The outcome of such an analysis
cannot be seen as solid evidence, but can help to get more
insight in the adverse drug reaction (ADR). The use of
measures like ROR and disproportionality can help to
detect drugs with an increased association with an ADR. A
statistically significant ROR may be indicative of a higher
risk for that particular event during the use of a specific
medication, but is never conclusive for the actual existence
of a causal relation [2].
The results of this study should alert physicians of the
risk of hypothermia in psychiatric patients using APDs.
There seems to be no direct relation between stable drug
dose and the ADR; the period shortly after starting the APD
or dose increase seems to be the high risk period. Often,
drug changes are indicated by behavioral problems also
leading to separation or isolation of the patient. In the case
of separation, patients will be dressed lightly and, even at
normal room temperature, can cool down easily. In these
cases, the patient’s body temperature should be monitored
daily (with a thermometer that can measure low body
temperatures). Also, every change in behaviour or co-
morbidity (e.g., infections) should be a warning sign to
look for hypothermia.
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